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THE purpose of this study was to test the hypothesis that
muscle proteolysis induced by TNF or IL-1 is mediated
by glucocorticoids. Rats were treated with 300/gg kg
-1 of
recombinant human preparations of IL-10t (rIL-10t) or
TNF0t (rTNF0t) divided into three equal intraperitoneal
doses given over 16 h. Two hours before each cytokine
injection, rats were given 5 mg kg-1 of the glucocorticoid
receptor blocker mifepristone RU 38486, by gavage or
were gavaged with the vehicle. Eighteen hours after the
first cytokine injection, total and myofibrillar protein
breakdown rates were determined in incubated extensor
digitorum longus muscles as release of tyrosine and 3-
methylhistidine, respectively. Total and myofibrillar pro-
teolytic rates were increased following injection of rIL-10t
or rTNF0t. Proteolysis induced by rIL-10t was not altered
by treatment with RU 38486. In contrast, the glucocorticoid
receptor blocker inhibited the proteolytic effect of rTNF0t.
The results suggest that the proteolytic effect of TNF
is mediated by glucocorticoids and that IL-1 induces
muscle proteolysis through a glucocorticoid independent
pathway.
Key words" Glucocorticoids" IL-I" Protein breakdown" Skele-
tal muscle; TNF.
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Introduction
Previous studies suggest that tumour necrosis
factor (TNF) and interleukin-1 (IL-1) can stimulate
muscle protein breakdown,
1-4 although conflicting
results have been reported. The mechanism by
which TNF and IL-1 exert this metabolic effect is
unknown. A direct effect on-protein metabolism
could not be verified when IL-1 or TNF was added
to incubated muscles. 5-8 Because both cytokines can
induce release of glucocorticoids
9-1 it has been
suggested that the metabolic effects of these
cytokines involve hormonal stimulation.1’2 The
purpose of this study was to test the hypothesis that
muscle proteolysis induced by TNF or IL-1 is
mediated by glucocorticoids. This was done by
administering the cytokines to rats that had been
treated with the glucocorticoid receptor antagonist
RU 38486.13
Materials and Methods
The study was performed using male Sprague-
Dawley rats weighing 40--60 g (Zivic-Miller Labor-
atories, Inc., Zelienople, PA). The animals were
housed in groups of three per cage at 22C room
temperature with a 12 h light/dark cycle, and were
allowed to acclimatize for 3 days before experi-
ments. Three series of experiments were performed.
In the first series of experiments, groups of rats
were treated with three intraperitoneal injections of
human recombinant IL-I (rIL-l), 100 #g kg-
body weight each, at 16" 00, 24"00 and 08"00 h. The
cytokine (kindly provided by Hoffman-La Roche,
Nutley, Nj) had a specific activity of 3 x 108
U mg- protein (D10 assay) and contained less than
0.75 endotoxin units/mg protein (determined by
Limulus lysate assay). The cytokine was diluted in
phosphate buffered saline (PBS), pH 7.4, to a final
concentration of 10 #g m1-1. Other rats received
corresponding intraperitoneal injections of PBS.
Both cytokine and PBS treated rats were divided
into two subgroups. Animals in one subgroup were
treated with three doses (5 mg kg
-1 body weight
each) of the glucocorticoid receptor antagonist RU
38486 (kindly provided by Roussel-Uclaf, Romain-
ville, France) administered by gavage 2 h before
each cytokine or PBS injection. RU 38486 was
suspended in an aqueous solution of 0.20%
polysorbate (Tween 80; Sigma Chemical Co., St.
Louis, MO) and 0.25% carboxymethylcellulose
(Sigma). Animals in the other subgroup received
corresponding volumes of the vehicle by gavage.
In the second series of experiments, an identical
protocol was employed except that human
recombinant TNF (rTNF) was injected instead
of rIL-l. The rTNF preparation (kindly provided
by Knoll Pharmaceuticals, Whippany, NJ) had a
specific activity of greater than 5 x 106U mg
-1
protein (L929 cytotoxicity test) with an endotoxin
content of less than 5 U mg
-1 protein (Limulus
lysate assay).
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Muscle protein breakdown rates were measured
2 h after the last cytokine or PBS injection. With
rats under ether anaesthesia, the extensor digitorum
longus muscles were dissected with their tendons
intact. The muscles were tied by their tendons on
stainless steel supports at resting length and
incubated individually in 3ml of oxygenated
(O2"CO2, 95" 5) Krebs-Henseleit bicarbonate buffer
(pH 7.4) with 10 mM glucose in a shaking water
bath at 37C. After preincubation for 30 min, the
muscles were incubated for 2 h in 3 ml of fresh
oxygenated medium of the same composition as
described above but also containing cycloheximide
(0.5 mM) to prevent reutilization of amino acids
released during proteolysis. Total and myofibrillar
protein breakdown rates were determined as release
of tyrosine and 3-methylhistidine (3-MH), respec-
tively, taking changes in tissue levels of the amino
acids during incubation into account, as described
in detail previously.
14
In the third series of experiments, we examined
the effect of rlL-l and rTNF0 on plasma levels of
corticosterone, the predominant glucocorticoid in
rodents, rIL-10 or rTNF0 was injected in-
traperitoneally at a dose of 100/g kg
-1 body
weight at 08"00h. Control animals received
corresponding volumes of PBS. Blood was
collected into heparinized beakers following decapi-
tation 30 min, 2 h, 4 h and 8 h after cytokine or PBS
injection. Blood was centrifuged and the plasma
was stored at --70C until assayed. Corticosterone
levels were determined by radioimmunoassay.
15
Results are presented as mean _SEM. For
statistical comparison analysis of variance followed
by Duncan’s multiple range test was used.
Differences were considered significant for
p < 0.05.
Results
Rats exhibited symptoms of lethargy, piloerec-
tion and loose stool following injection of rlL-l
or rTNF, and these symptoms were slightly more
prominent following rlL-l than rTNF0 admin-
istration. There was no mortality when rlL-l or
rTNF was injected into rats that had not been
treated with RU 38486. In the groups of rats that
had been treated with RU 38486, mortality rates
following rlL-10 and rTNF0 were 33% (10/30) and
7% (2/30), respectively.
Total protein breakdown rate, expressed as
tyrosine release, was increased by 46% and
myofibrillar protein breakdown rate, expressed as
3-MH release, was increased more than two-fold
following administration of rlL-l (Fig. 1).
Treatment with RU 38486 did not alter the effect
of rlL-l on total or myofibrillar protein
breakdown rates (Fig. 1). The glucocorticoid
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FIG. 1. The effect of rlL-l (100 #g kg -1 bw 3) on total (upper panel)
and myofibrillar protein (lower panel) breakdown rates following
treatment with RU 38486 (5 mg kg -1 bw x 3) or sham gavage,
n 13-15 per group; *p < 0.05 vs the corresponding control group.
receptor antagonist did not affect protein break-
down rates in control injected rats.
Following administration of rTNF, total and
myofibrillar protein breakdown rates were in-
creased by approximately 40% and 60%, respec-
tively (Fig. 2). This increase in protein breakdown
rates was completely blocked by RU 38486 (Fig. 2).
Plasma corticosterone levels were increased 30
min after rIL-10 or rTNF0 administration and
remained elevated for at least 4 h (Fig. 3). The
response of plasma corticosterone levels was similar
to the two cytokines.
Discussion
The present results confirmed previous studies
from this and other laboratories showing that both
IL-104 and TNF02’s’6 can induce muscle proteolysis
when administered to experimental animals. The
study also showed that the increase in muscle
protein breakdown, induced by rIL-10, was not
affected by RU 38486, whereas TNF-induced
muscle proteolysis was completely blocked by the
glucocorticoid receptor antagonist. The results
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FIG. 2. The effect of rTNF (100 #g kg -1 bw 3) on total (upper panel)
and myofibrillar protein (lower panel) breakdown rates following
treatment with RU 38486 (5 mg kg -1 bw x 3) or sham gavage.
n 11-13 per group; *p < 0.05 vs all other groups.
suggest that TNF-induced muscle protein break-
down is mediated by glucocorticoids and that IL-1
stimulates muscle protein breakdown by other
mechanism(s). Muscle protein synthesis was not
determined in the present study because previous
reports suggest that IL-1 and TNF do not regulate
protein synthesis in skeletal muscle. 3’4
RU 38486 is a potent glucocorticoid receptor
antagonist with no agonist activity even at high
concentrations.
13 The effectiveness of RU 38486 to
block glucocorticoid receptors in different tissues,
including skeletal muscle, was demonstrated
previously.
17 At a dose of 5 mg kg-
body weight,
RU 38486 blocked approximately 90% of gluco-
corticoid receptors in rat muscle 2 h after
administration.
7 Chronic administration of the
blocker inhibited dexamethasone-induced muscle
atrophy. A dose of 15 mg kg
-1 body weight
given over 16 h, identical to the protocol used in
the present study, completely prevented the
proteolytic effect in rat muscle seen following
injection of 200 mg kg-
body weight of corti-
4 costerone.
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FIG. 3. Plasma corticosterone levels following administration of rlL-l,
rTNF (lO0#gkg -1 bw) or control injection, n=4-5 per group.
*p < 0.05 vs control.
The present result of glucocorticoid independent
stimulation of muscle proteolysis following admin-
istration of rlL-lz is in line with a recent study from
our laboratory.
4 Because in other studies IL-1 did
not increase muscle protein degradation when
added directly to incubated muscles, even at high
concentrations,
5-8 it is not likely that muscle
proteolysis following the administration of IL-1 in
vivo reflects a direct effect on muscle. It is not known
at present by which mechanism(s) IL-1 stimulates
protein degradation in skeletal muscle. It may be
speculated that catabolic hormones other than
glucocorticoids, fever, haemodynamic changes and
other steroid independent eEects induced by IL-1
may account for its metabolic effects in muscle
tissue.
In contrast to IL-1, the current study suggests
that TNF requires the action of glucocorticoids to
induce muscle protein breakdown. These results are
in line with previous reports in which TNF-induced
muscle catabolism was prevented by adrenal-
12,18 The effect of RU 38486 on muscle ectomy.
proteolysis following TNF has not been reported
previously. It should be noted that although the
present results suggest that TNF-induced muscle
proteolysis is mediated by glucocorticoids, the
results may also be consistent with the concept that
glucocorticoids act as a co-factor to TNF. Indeed,
previous studies, in which TNF was administered
to rats alone or in combination with corticosterone,
suggest that glucocorticoids are an important
cofactor to the cytokine.
18 Regardless of whether
glucocorticoids act as a cofactor or as a second
mediator released by TNF, the present study
confirms that glucocorticoids are required for TNF
to induce muscle protein breakdown.
Although the present results suggest that IL-1
and TNF stimulate muscle proteolysis through
different mechanisms, other explanations need to be
considered as well. For example, if IL-1 resulted in
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a more prominent release of glucocorticoids than
TNF, the dose of RU 38486 may have been
insufficient to block the effect of IL-1. Although
plasma corticosterone levels were almost identical
following a single injection of rIL-10 or rTNF0 in
the present study, it should be noted that plasma
hormone levels may be different following repeated
injections of the cytokines. In a recent study, mice
became refractory to induction of serum corti-
costerone following repeated injections ofTNF but
not following repeated injections of IL-1.19
Because previous studies, both in vivo and in vitro,
have demonstrated that TNF stimulates the release
of IL-1 from macrophages and endothelial cells,2’21
it is possible that the increased muscle protein
breakdown, observed in the current experiments,
was the result of IL-1 even when rats were treated
with TNF and that TNF-induced release of IL-1
was mediated by glucocorticoids. Further experi-
ments are required to resolve this issue. The
interaction between IL-1, TNF and glucocorticoids
is further complicated by the fact that exogenous,
and possibly endogenous, glucocorticoids may
affect cytokine production.
22-24
The present results are important from a clinical
standpoint because both IL-1 and TNF have been
implicated as regulators of muscle protein break-
down during sepsis. 1’3’25 Sepsis results in increased
degradation of muscle protein, in particular
myofibrillar proteins,
26 similar to the response seen
here following administration of IL-1 or TNF.
Recent studies in our laboratory, using anti-TNF
antibodies
3 or IL-1 receptor antagonists (un-
published observations) in septic rats support the
concept that both cytokines are involved in the
regulation of muscle protein breakdown during
sepsis. When septic rats were treated with RU
38486, the increase in muscle protein breakdown
was blunted but not completely blocked,
27 sug-
gesting that sepsis-induced muscle proteolysis is
mediated both by glucocorticoid dependent and
glucocorticoid independent pathways. From the
results in the present study it may be speculated that
during sepsis glucocorticoids mediate the effect of
TNF, whereas IL-1 stimulates muscle proteolysis
through a glucocorticoid independent pathway.
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